Resumen de A case report of ledipasvir-sofosbuvir off-label use in a 10 years old pediatric patient
Felix Gómez de Rueda, Bárbara Cancela Díez, María Eugenia Tena Sempere, A. Pérez-Parras, Ana Arévalo Garrido
Ledipasvir-Sofosbuvir (LDV/SOF) is a novel fixed-dose combination of Direct-acting antiviral Agents (DAA), marketed for the treatment of hepatitis C virus, genotypes 1, 4, 5 or 6. It is an association of powerful inhibitors of NS5A protein and NS5B polymerase, essential for RNA replication. The aim of this case report is to share a sentinel experience of a hepatitis C genotype 1 in a 10-year-old infant case, who after evaluating his evolution and the current availability of novel direct-acting antivirals, decided to treat with ledipasvir-sofosbuvir with adult doses. Despite being a child, his weight, height and BMI (body mass index), were definitive to treat him with adult doses as an off-label treatment. This decision was taken into consideration by the pediatricians after they asked for a query to the Digestive and Hospital Pharmacy Units, which supervised at all times the evolution of the patient and their pharmacotherapeutic results
